Overview

A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Glucagon-Like Peptide 1
Liraglutide
rGLP-1 protein